With Bristol-Myers Squibb Co.'s sales of its PD-1 inhibitor Opdivo still strong but slipping behind Merck & Co. Inc.'s competing Keytruda, the company is under pressure to acquire new assets as a backup plan.
Amid PD-1 Uncertainty, Bristol Under Pressure For M&A Activity
Bristol says its checkpoint immunotherapies can hold the lead in renal cell carcinoma, despite increasing competition.
More from Immuno-oncology
More from Anticancer
• By
The acquisition is worth up to $1bn and adds to AstraZeneca’s broad array of cell therapy technologies.
• By
The Singapore and Seattle-based biotech is joining the race to bring a ‘double whammy’ antibody-drug conjugate to patients.
• By
A Phase III trial testing the protein degrader in breast cancer met the primary endpoint and showed an efficacy benefit only in the subgroup of ESR1 mutant patients, not the full population.